Does BROLUCIZUMAB-DBLL Cause Polypoidal choroidal vasculopathy? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Polypoidal choroidal vasculopathy have been filed in association with BROLUCIZUMAB-DBLL. This represents 0.4% of all adverse event reports for BROLUCIZUMAB-DBLL.
10
Reports of Polypoidal choroidal vasculopathy with BROLUCIZUMAB-DBLL
0.4%
of all BROLUCIZUMAB-DBLL reports
0
Deaths
0
Hospitalizations
How Dangerous Is Polypoidal choroidal vasculopathy From BROLUCIZUMAB-DBLL?
Of the 10 reports.
Is Polypoidal choroidal vasculopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BROLUCIZUMAB-DBLL. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does BROLUCIZUMAB-DBLL Cause?
Vitreous floaters (479)
Visual impairment (446)
Vision blurred (416)
Eye inflammation (387)
Visual acuity reduced (365)
Retinal vasculitis (323)
Uveitis (305)
Vitritis (284)
Eye pain (234)
Vitreous opacities (205)
What Other Drugs Cause Polypoidal choroidal vasculopathy?
Which BROLUCIZUMAB-DBLL Alternatives Have Lower Polypoidal choroidal vasculopathy Risk?
BROLUCIZUMAB-DBLL vs BROMAZEPAM
BROLUCIZUMAB-DBLL vs BROMFENAC
BROLUCIZUMAB-DBLL vs BROMHEXINE
BROLUCIZUMAB-DBLL vs BROMOCRIPTINE
BROLUCIZUMAB-DBLL vs BROTIZOLAM